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Abstract
As the society begin to realize the importance of combating antimicrobial resistance, going 
back to silver might be the solution. Silver has been known for its potential antimicrobial 
activity since ancient times and, the development of nanoparticles has increased its potential 
into becoming an antimicrobial agent that can be applied in broad-spectrum. Antimicrobial 
resistance has spread into an irrepressible manner which requires drastic action plan as a number 
of pathogenic bacteria began to acquire resistance genes. Methicillin Resistant Staphylococcus 
aureus (MRSA) is one of the earliest reported resistant clones which is the center of this study. 
This study focused on the dissemination and evolution of MRSA on its resistance towards 
antibiotics. Disc Diffusion Test was employed to create the antibiograms of MRSA isolates. All 
isolates showed resistance towards amoxicillin, ampicillin, cefazolin, oxacillin and penicillin. 
In contrast, all isolates were susceptible towards erythromycin. The findings also discovered 
isolates that were vancomycin-resistant (66.7%) and vancomycin-intermediate (33.3%). As the 
efficacy of antibiotic treatment is at a question, we also investigated on the antimicrobial activity 
of colloidal silver in the hope as an alternative treatment. Shiga Toxin producing Escherichia 
coli (STEC) and MRSA (ATCC 33591) was tested using modified Quantitative suspension 
test for the evaluation of bactericidal activity for chemical disinfectants and antiseptics based 
on BS EN 1276:2009. The outcome of this study indicated that the colloidal silver is working 
effectively against STEC and MRSA (ATCC 33591), showing killing percentages well above 
99.0% at 4 minutes and 8 minutes of contact. Vancomycin-resistant S. aureus (VRSA) and 
Vancomycin-intermediate S. aureus (VISA) were also tested and the results indicated that 
VISA had higher killing percentages at 4 minutes (99.83%) and 8 minutes (99.85%) compared 
to VRSA at 4 minutes (96.72%) and 8 minutes (98.35%).  This opens a solution to the rising 
problem of antimicrobial resistance.
Introduction
Silver, a precious metal that was known long for 
its shining properties alongside gold was reported to 
have antimicrobial properties. From the ancient times, 
silver vessels were used as a disinfectant to store and 
purify water. The theory is also now currently used 
by the National Aeronautics Space Administration 
(NASA) for water storage and purification in its 
space shuttle. The mechanism action of silver’s 
antimicrobial properties was extensively studied by 
many researchers to date. The metal in pure form 
is inert and does not react with human tissue or kill 
microorganisms until it is ionized (Melaiye and 
Youngs, 2005). Silver ions were reported to inhibit 
bacterial growth through protein inactivation where 
by it forms stable S-Ag bond with thiol-containing 
compounds in the cell membrane that are involved 
in transmembrane energy generation and ion 
transport (Klueh et al., 2000). Subsequently, this 
lead to membrane damages and cause apoptosis 
through oxidative damages as reported by Cheng 
et al. (2013). Silver ions can also act as a catalyst 
in oxidation reactions that results in the formation 
of disulfide bonds, which could possibly change 
the cellular enzymes and subsequently affect their 
function (Davies and Etris, 1997). This is to say 
that silver ions have the potential to inactivate 
essential enzymes, particularly cellular enzymes. 
This will disrupt the organisms’ respiratory path by 
obstructing metabolic activity, and lead to death. On 
the other hand, silver was proposed to cause RNA or 
DNA alteration. Klueh et al. (2000) explained that 
it was possible that silver ions enters the cell and 
intercalates between the purine and pyrimidine base 
pairs, disrupting the hydrogen bonding between the 
two anti-parallel strands. This denatures and inhibits 
bacterial replication.
The antimicrobial properties of silver are further 
enhanced when nanotechnology surfaced. Through 
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simple electrochemistry and irradiation under short 
wavelengths of light, nanoparticles silver also known 
as colloidal silver can be produced. Colloids are 
clusters of silver atoms that carry the same electrical 
charge, and thus mutually repel each other (Laroo, 
2013). Clusters of silver atoms can be from a single 
monomer to millions of atoms forming many sizes 
in one dimension. Clusters larger than 100 nm in 
one dimension are no longer considered to fall 
in the category of nano clusters (Laroo, 2013). 
Nano particles size of silver increase the surface 
area to volume ratio, allowing the silver particles 
to penetrate through easily into the organism and 
cause destruction (Martinez-Castanon et al., 2008). 
The smaller the size, the better. Colloidal silver is 
usually suspended in a solution, usually water, to 
prevent agglomeration and maintain effectiveness. 
The suspension is well-maintained through the 
presence of highly negative Zeta-potential which 
causes the mutual repelling action (Laroo, 2013). A 
slight disruption or contamination on the negatively 
Zeta-potential will cause agglomeration. Other than 
that, nano silver is coated with coating agents that are 
non-covalently attached to maintain an equilibrium 
state such as citric acid, various amino acids, cetyl 
trimethylammonium bromide (CTAB), and sodium 
dodecyl sulfate (SDS) (McShan et al., 2014). 
The present study investigates on the antimicrobial 
activity of colloidal silver against Shiga Toxin 
producing Escherichia coli (STEC) and Methicillin 
Resistant Staphylococcus aureus (MRSA); the two 
pathogens that most feared of having the capabilities 
to be increasingly resistant and endangering the 
public’s health. As the antimicrobial resistance 
becomes an alarming matter, many researchers are 
looking for alternative ways and treatments. Before 
that, we created an antibiogram profile of MRSA to 
study on its antibiotic resistance evolution. 
Materials and Method
Bacterial Strains 
Staphylococcus aureus (ATCC 33591) defined as 
Methicillin resistant was used in this study. On the 
other hand, wild-type Staphylococcus aureus was 
also isolated from poultry sampled from Serdang, 
Malaysia through conventional method as stated 
in Bacteriological Analytical Method (BAM) by 
Bennett and Lancette (2001) with modification using 
selective media Mannitol Salt Agar (MSA) [Merck, 
Germany]. A total of 30 isolates were collected 
and all of the isolates were streaked onto OxoidTM 
BrillianceTM MRSA 2 Agar [Thermo Oxoid, United 
Kingdom] for confirmation purpose. Out of 30 
isolates, 9 isolates produced presumptive colonies 
of MRSA that produced denim blue colonies. The 
isolates were picked and kept on nutrient agar slants 
until further used. All presumptive colonies of MRSA 
were subjected to Antibiotic Susceptibility Testing 
according to Bauer et al. (1966) for antibiogram 
profiling.
Escherichia coli was isolated from ready-to-
eat food through conventional methods as stated in 
Bacteriological Analytical Method (BAM) by Feng 
et al. (2002). It was then subjected to Polymerase 
Chain Reaction (PCR) for Shiga Toxin identification 
using targeted genes of stx 1 (Shiga toxin 1) and stx 2 
(Shiga toxin 2) (Gannon et al., 2012). PCR conditions 
used were referred to Bai et al. (2010). The PCR 
products were subjected to gel electrophoresis using 
1.25% of Agarose at 80 V for an hour. It was then 
viewed under UV light using GeneSnap [Syngene, 
United Kingdom]. Identified Shiga Toxin producing 
E. coli (STEC) were then grown on nutrient agar 
slants until further used. 
Antibiotic susceptibility testing 
The antibiotic susceptibility testing was performed 
according to Bauer et al. (1966) with modifications. 
Briefly, isolates were inoculated into Luria-Bertani 
(LB) Broth [Nacalai Tesque, Japan] and incubated 
for 24 hours at 37oC. The bacteria suspension was 
then spread using sterile cotton swab onto Mueller-
Hinton Agar [Difco, USA] plates and allowed to 
dry. Antibiotic discs were arranged neatly using 
sterile forceps onto the swabbed plates before they 
are inverted and incubated for 24 hours at 37oC. The 
antibiotics used in this test were amoxicillin (25 µg), 
ampicillin (25 µg), cefazolin (30 µg), ciprofloxacin 
(10 µg), erythromycin (15 µg), kanamycin (30 µg), 
norfloxacin (10 µg), oxacillin (1 µg), penicillin (10 
µg), tetracycline (10 µg), trimethoprim (5 µg) and 
vancomycin (30 µg); all purchased from Oxoid. 
After incubation, the diameters of the zone inhibition 
were measured and tabulated as according to Clinical 
and Laboratory Standards Institute (CLSI) for 
categorizing. 
Colloidal silver denotation
The initial count of the bacteria was prior 
performed through plate counting method. Briefly, 
the bacteria was inoculated into nutrient broth and 
allowed to grow for 3 hours at 37°C. Prior to the 
experiment, a growth curve of each bacteria was 
plotted using plate counting method and, it was 
observed that a 3 hour growth was sufficient to have a 
count of well above 5 log CFU/ml (Data not shown). 
It was then subjected to 10 times of ten-fold serial 
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dilutions. For each dilution, 1 ml of the diluent was 
pipetted into duplicate sterile petri dish and added 
with sufficient amount of Plate Count Agar (PCA). 
It was then incubated at 37°C for 18 to 24 hours. The 
colonies formed were identified and enumerated. 
Colloidal silver was obtained commercially. 9 
ml of colloidal silver was transferred into a sterile 
test tube. The colloidal silver suspension was placed 
into the water bath at 20°C. 1 ml of 3 hour growth 
of bacterial suspension, initial count ranging from 
5 log CFU/ml to 7 log CFU/ml in nutrient broth 
[Merck, Germany] was added into the colloidal 
silver suspension and the start watch was started 
immediately. The suspensions were allowed to mix 
according to the chosen contact times which were 
4 minutes and 8 minutes. Immediately, after the 
chosen contact time, 1 ml of the mixed suspensions 
was transferred into another tube containing 1 ml of 
sterile distilled water and 8 ml of neutralizer (0.1% 
sodium sulphate, Na2SO4 [Merck, Germany]). It was 
allowed to stand for 5 minutes before performing 
serial dilutions where by 1 ml of the solution was 
pipetted and, serially diluted for ten-folds for six 
times in 0.85% saline, NaCl, solution. 1 ml of each 
dilution was pipetted out into duplicates empty petri 
dishes and added with standard method agar (SMA). 
Once the agar had been solidified, the plates were 
incubated at 37°C for 18 to 24 hours. The colonies 
formed were identified, enumerated and tabulated. 
The killing percentage was calculated following the 
equation [final count (CFU/ml) – initial count (CFU/
ml)/initial count (CFU/ml)]. 
Results and Discussion
Staphylococcus aureus was reported as the first 
pathogen that acquired resistivity against antibiotic 
treatment in 1960s, namely methicillin after a year 
it was introduced. Strains that showed resistivity 
towards beta-lactam antibiotics are classified as 
Methicillin resistant S. aureus (MRSA). The pathogen 
is constantly evolving with higher resistivity and 
the efficacy of antibiotic treatment might be non-
relevant in the future. In this study, out of 30 isolates 
collected from poultry, 9 (30.00%) of the isolates 
were identified as positive wild-type MRSA. This 
signified the fast spreading of the pathogen and 
it is not only an issue anymore in the hospitals 
that is one of the important reservoirs of MRSA. 
Rajaduraipandi et al. (2006) indicated that infected 
or colonized patients and transient hand carriage on 
the health care workers is the predominant mode for 
patient to patient transmission. Subsequently, when 
the infected or colonized patients are discharged, 
it widens the possible route of transmission of the 
pathogen and exacerbated the problem. In addition, 
the emergence of MRSA could happen simply 
through the horizontal gene transfer or transduction 
of mobile drug resistance genes from important 
reservoirs such as the wastewater and hospitals. It 
is no wonder the prevalence of MRSA leaps from 
year to year as reported by the National Nosocomial 
Infection Surveillance (NNIS) System data that 
demonstrated a steady increase in the incidence 
of nosocomial infections (NNIS, 2004). In 2010, a 
survey was conducted on the MRSA prevalence by 
Jarvis et al. (2012) and, they concluded that MRSA 
colonization has increased.  
The 9 positive wild-type MRSA isolates were 
tested with 12 different antibiotic discs of different 
groups that have reported to be used against 
staphylococcal infection and, the antibiogram 
profile was as shown in Figure 1. Based on Figure 
1, it was evaluated that all wild-type MRSA isolates 
were 100% resistant against amoxicillin, ampicillin, 
cefazolin, oxacillin, and penicillin. This further 
confirms the isolates were indeed MRSA based on the 
resistance towards amoxicillin, ampicillin, oxacillin 
and penicillin; all of those mentioned are beta-lactam 
antibiotics. The results also substantially prove that 
cefazolin, a suitable first-generation cephalosporins 
will not be effective against staphylococcal 
infection. On the other hand, erythromycin remained 
bactericidal against the wild-type MRSA isolates 
as shown in Figure 1. According to Harbarth et al. 
(1999), hospital acquired MRSA are resistant to 
erythromycin while community acquired MRSA 
are susceptible, although it may range up to 25% 
of resistance. Hence, the isolates were classified 
as community-acquired MRSA, a pathogen well-
described in the general population. Community-
acquired MRSA typically affects community that 
lacks of hospital association and, it can cause serious 
and fatal infections in otherwise healthy hosts (Naimi, 
2001). None of the isolates were resistant indicating 
Figure 1. Antibiogram profile of wild-type MRSA 
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that it can be used as antibiotic treatment suitable for 
minor skin infections through oral route. Despite that, 
the wild-type MRSA isolates began to show high 
resistance against Kanamycin, an antibiotic used to 
treat a wide variety of infections. About 88.9% of 
the isolates were resistance and it is likely that in the 
later years, it will be fully resistant to Kanamycin, 
rendering it ineffective. 66.7% of the isolates were 
resistant towards tetracycline in support of a recent 
finding reported by Turnidge et al. (2008) of MRSA’s 
resistivity towards tetracycline while 44.4% of the 
isolates were resistant to trimethoprim, ciprofloxacin 
and norfloxacin. 
Hiramatsu (2001) reported a new strain of S. 
aureus that was resistant towards vancomycin and this 
strain was termed as vancomycin-resistant S. aureus 
(VRSA). Similar strains have been detected in this 
study in which about 6 out of 9 isolates (66.7%) were 
resistant. Vancomycin use to be the drug of choice 
for serious infections caused by S. aureus strains. 
However, the reported results indicated otherwise and 
the occurrence of the strain was explained by Finks 
et al. (2009) in which they concluded that patients 
were co-infected or co-colonized with vancomycin 
resistant enterococci (VRE) and MRSA, which 
enables transfer of vanA gene from VRE to MRSA 
in a biofilm environment leading to a VRSA strain. 
Daum et al. (1992) reported that VRSA strains were 
found to have thicker peptidoglycan wall which may 
reduce the efficacy of antibiotics targeting cell walls. 
The remaining three isolates (44.4%) were reported 
as vancomycin-intermediate S. aureus (VISA). The 
disc diffusion test conducted can be considered as 
the acceptable primary test methods as mentioned 
by the Centers for Disease Control (CDC) and it is 
suggested for re-testing for further confirmation. 
Multidrug resistant bacteria have created 
therapeutic problems especially to healthcare 
providers and, its consistent emergence will only 
cause hazard to the public health. The antibiogram 
profile created for all 9 isolates indicated different 
types of MRSA, primarily community-acquired 
MRSA as mentioned earlier. All isolates (100.0%) 
had a high MAR index of more than 0.2 with a range 
from 0.50 to 0.92. Two of the isolates (22.2%) were 
resistant to eleven types of antibiotics with a MAR 
index of 0.92. In contrast, only one isolate (11.1%) 
had a different antibiotic pattern and was resistant to 
six types of antibiotics. This signified that the bacterial 
isolates have been exposed to several antibiotics and 
the selective pressure of the antibiotics used in the 
management of bacterial infections could be the main 
reason of resistance (Poonia et al., 2014) apart from 
the bacteria acquiring the resistance gene via mutation 
or interspecies gene transmission. Laximanarayan et 
al. (2013) noted that resistance genes of pathogens 
were borne on chromosomal and increasingly, on 
transmissible extrachromosomal elements. 
The wild-type MRSA isolates were obtained 
from poultry. The most likely source of resistant 
bacteria in food of animal origin is contamination 
from the animals’ intestines during slaughter as stated 
by Laximanarayan et al. (2013). Contamination 
can possibly occur at every stage when there is 
insufficient food hygiene and sanitation. The spread 
of MRSA from people to animals either directly or 
indirectly has been well-reported (Catry et al., 2010). 
Most importantly, the fact that resistance genes can 
be transferred between different commensal bacterial 
species and from those to pathogens adds on to 
the complexity of numerous possible pathways of 
transmission of resistant bacteria. 
The efficacy of antibiotics have decreased in 
recent years and the cause of it is complex. It is 
possible that it is due to many factors that lead in 
a stepwise fashion and as a result, the community 
is facing the emergence of resistant clones such 
as MRSA, Escherichia coli ST131 and Klebsiella 
ST258. The resistance is spreading worldwide and 
it has become a global epidemiology as those most 
vulnerable are at risk. For high-income countries, 
antibiotic resistance is treated with high rates and 
prolonged antibiotic use and if it is not effective, 
more expensive and broad-spectrum antibiotics will 
be used. As for low-income and middle-income 
countries, the aftermath of resistant which leads to 
high mortality rate, high hospitalization rate and high 
prevalence of hospital infections. Nevertheless, the 
burden of resistance is felt across the globe: longer 
duration of illness, higher rates of mortality in patients 
with resistant infection, increasing costs of treatment 
for resistant infections, and inability to do procedures 
that rely on effective antibiotics to prevent infection 
(Laximanarayan et al., 2013). 
Tackling antibiotic resistance is not a simple task. 
It requires good operational excellence with detailed 
planning, execution and monitoring. Researchers are 
currently putting their heads together to intervene the 
spread of antibiotic resistance. Besides focusing on 
creating a stronger and effective antibiotic, research in 
molecular biology had yet to come out with solutions 
such as stopping plasmid replication (DeNap and 
Hergenrother, 2005) or resistance mechanisms such 
as efflux pump inhibitors (Kurincic et al., 2012) as 
well as bacteriophage treatment. Colloidal silver, on 
the other hand, has high antimicrobial properties as 
reported by many researchers (Kvitek et al., 2011; 
Rai et al., 2012; Laroo, 2013). When tested against 
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MRSA either ATCC or wild-type, the results (Figure 
2) were substantial to prove its efficacy and can be 
recommended as a possible intervention solution of 
antibiotic resistance. 
The killing percentage of MRSA (ATCC 
33591) recorded was 99.03% (2.01 log reduction) 
and 99.24% (2.12 log reduction) for 4 minutes and 
8 minutes respectively. Two types of wild-type 
MRSA with Vancomycin-resistant and Vancomycin-
intermediate were selected and labelled as VRSA and 
VISA. The results as shown in Figure 2 did not differ 
as much from MRSA (ATCC 33591). The killing 
percentage of VISA was 99.83% (2.78 log reduction) 
and 99.85% (2.81 log reduction) for 4 minutes and 
8 minutes respectively. In contrast, VRSA recorded 
slight difference with a drop in killing percentage at 
4 minutes (96.72%, 1.48 log reduction) and also at 
8 minutes (98.35%, 1.78 log reduction). The most 
probable reason of VRSA to have a lower killing 
percentage could be due to the thick peptidoglycan 
layer of the bacteria. Aforementioned, VRSA has the 
ability to produce thicker cell walls (Daum et al., 
1992). Consequently, the thick peptidoglycan layer 
minimized the ability of colloidal silver to penetrate 
into the bacterial cell. Kawahara et al. (2000) added 
that the peptidoglycan layer is negatively charged 
and the colloidal silver might get trapped by the 
peptidoglycan due to charges attraction as the charge 
surrounding the clusters of silver atoms is positively 
charged. 
We tested the colloidal silver with another 
pathogen, Shiga Toxin producing E. coli (STEC) and 
the results were as satisfactory as MRSA (Figure 2). 
The killing percentage of STEC at 4 minutes and 
8 minutes were 99.62% (2.42 log reduction) and 
99.93% (3.15 log reduction) respectively. It was 
observed that Gram-negative bacteria were more 
susceptible to colloidal silver due to the absence of 
the peptidoglycan layer which supports the higher 
killing percentage when compared to Gram-positive 
bacteria. Based on the results, colloidal silver had 
indeed shine itself as an alternative to antibiotic 
resistance and could possibly be the next antibiotic. 
The incorporation of colloidal silver into medicine 
had begun since 1990s but there were insufficient 
extensive studies on its toxicity as it is a metal. 
Examples of application include wound dressing, 
endotracheal tubes, surgical masks, and cotton fibers. 
The concept of application generally only involves 
coating of the colloidal silver onto the items. As 
such, this prevents the spread of infectious bacteria 
and subsequently reduces the rate of infection. On the 
other hand, consumption of colloidal silver as a dietary 
supplement, however, was not widely recommended 
due to side effects of long-term ingestion of gram 
quantities of silver (Silvestry-Rodriguez et al., 
2007) where one will be suffering from argyria. 
The colloidal silver product used as a tested sample 
was found to be effective against MRSA and STEC 
at low concentration of colloidal silver (10 ppm). 
This is supported by Laroo (2013) by stating that the 
minimum inhibitory concentration of colloidal silver 
to exhibit its antimicrobial properties can be as low as 
0.6 ppm compared to silver ions at 72 ppm or more. 
Note that, the minimum NOAEL (No Observable 
Adverse Effect Level) of silver is 10 g established 
by the World Health Organization (WHO) in 1996 
in which the ingestion of the colloidal silver product 
should not cause toxicity. In a study of comparison 
between nano silver and ionic silver, conducted 
by Kvitek et al. (2011), it was stated that colloidal 
nano silver displayed more significant antimicrobial 
activities at low concentrations that are not toxic 
against human cells and does not cause harm to the 
environment. It can be suggested as an alternative 
antibiotic for consumption to reduce colonization 
of MRSA in patients but the intake should be kept 
to a standard regulatory and the patients are fully 
consulted by a physician.  
Conclusion
The wide spread of MRSA into the food 
commodities at present, presents a risk to the public 
health. The hazard of the pathogen exacerbates 
as its increasing resistance towards antibiotic was 
observed via the antibiogram profile and the MAR 
index. To combat antibiotic resistance, colloidal 
silver was tested to be suitable as an alternative 
strategy for treatment due to its efficient antimicrobial 
Figure 2. The killing percentages of different contact times 
according to the tested pathogens. STEC: Shiga toxin 
producing Escherichia coli; MRSA: Methicillin Resistant 
Staphylococcus aureus; VISA: Vancomycin-intermediate 
Staphylococcus aureus; VRSA: Vancomycin-resistant 
Staphylococcus aureus
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properties as shown in the killing percentages of the 
pathogen MRSA (ATCC 33591 and wild-type) and 
STEC recorded well above 96% at 4 minutes and 8 
minutes. The complexity of antimicrobial resistance 
and the solution to solve it is never an easy task. 
As the consequences affect everyone in the world, 
alternative treatment and strategies holds a key 
in combating antimicrobial resistance should be 
considered in safeguarding the future.  
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